These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 2758102

  • 1. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.
    Kaiser G, Ackermann R, Brechbühler S, Dieterle W.
    Biopharm Drug Dispos; 1989; 10(4):365-76. PubMed ID: 2758102
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
    King JN, Maurer M, Morrison CA, Mauron C, Kaiser G.
    Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
    [Abstract] [Full Text] [Related]

  • 3. The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose.
    Waldmeier F, Kaiser G, Ackermann R, Faigle JW, Wagner J, Barner A, Lasseter KC.
    Xenobiotica; 1991 Feb; 21(2):251-61. PubMed ID: 2058180
    [Abstract] [Full Text] [Related]

  • 4. Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril.HCl.
    King JN, Humbert-Droz E, Maurer M.
    J Vet Pharmacol Ther; 1999 Dec; 22(6):360-7. PubMed ID: 10651464
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
    King JN, Mauron C, Kaiser G.
    Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
    King JN, Maurer M, Toutain PL.
    J Vet Pharmacol Ther; 2003 Jun; 26(3):213-24. PubMed ID: 12755906
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly.
    Kaiser G, Ackermann R, Dieterle W, Durnin CJ, McEwen J, Ghose K, Richens A, Holmes IB.
    Eur J Clin Pharmacol; 1990 Jun; 38(4):379-85. PubMed ID: 2344861
    [Abstract] [Full Text] [Related]

  • 8. The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride.
    Kaiser G, Ackermann R, Gschwind HP, James IM, Sprengers D, McIntyre N, Defalco A, Holmes IB.
    Biopharm Drug Dispos; 1990 Dec; 11(9):753-64. PubMed ID: 2271751
    [Abstract] [Full Text] [Related]

  • 9. Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers.
    Chan KK, Buch A, Glazer RD, John VA, Barr WH.
    Pharm Res; 1994 Mar; 11(3):432-7. PubMed ID: 8008712
    [Abstract] [Full Text] [Related]

  • 10. Disposition of [14C]-benazepril hydrochloride in rat, dog and baboon. Absorption, distribution, kinetics, biotransformation and excretion.
    Waldmeier F, Schmid K.
    Arzneimittelforschung; 1989 Jan; 39(1):62-7. PubMed ID: 2719745
    [Abstract] [Full Text] [Related]

  • 11. The pharmacokinetics of benazepril relative to other ACE inhibitors.
    Gengo FM, Brady E.
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV44-50; discussion IV51-5. PubMed ID: 1893642
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
    Kitagawa H, Eguchi T, Kitoh K, Ohba Y, Kondo M, Nakano M, Sasaki Y.
    J Vet Med Sci; 2000 Feb; 62(2):179-85. PubMed ID: 10720188
    [Abstract] [Full Text] [Related]

  • 14. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
    Toutain PL, Lefebvre HP, King JN.
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1087-93. PubMed ID: 10688627
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function.
    Shionoiri H, Ueda S, Minamisawa K, Minamisawa M, Takasaki I, Sugimoto K, Gotoh E, Ishii M.
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):348-57. PubMed ID: 1279278
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
    King JN, Strehlau G, Wernsing J, Brown SA.
    J Vet Pharmacol Ther; 2002 Oct; 25(5):371-8. PubMed ID: 12423228
    [Abstract] [Full Text] [Related]

  • 20. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
    Cawello W, Boekens H, Waitzinger J, Miller U.
    Int J Clin Pharmacol Ther; 2002 Jan; 40(1):9-17. PubMed ID: 11837383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.